DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Celgene (NASDAQ: CELG)

119.16 -1.71 (-1.41%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

CELG $119.16 -1.41%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $119.49
Previous Close $120.87
Daily Range $118.89 - $124.29
52-Week Range $66.85 - $124.60
Market Cap $95.2B
P/E Ratio 50.57
Dividend (Yield) $0.00 (0.0%)
Volume 8,137,019
Average Daily Volume 5,977,160
Current FY EPS $3.26





Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website:

News & Commentary

Big Pharma: An Up-Close Look at One Key Player

Industry Focus zooms in on restructuring, new drugs, and possible threats for pharma giant Novartis.

2 Biotech Juggernauts That Belong In Every Growth Portfolio

Did Researchers Just Discover the Cause of Pancreatic Cancer?

Pancreatic cancer is the fourth-leading cause of cancer-related death, but researchers may have moved one step closer to discovering a cure this past week.

3 Biotech Giants That Shouldn't Pay a Dividend

Three Motley Fool contributors explain why they don't want these large-cap biotech companies to pay a dividend.

Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog

Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog

Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog

Update: Celgene Continues To Have A Large Gap In Its GAAP Reporting

Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Regeneron Shows Biotech Investors Have Left Their Wildcatting Days

Celgene's EPS Contain 'Few Surprises,' Baird Says

See More CELG News...

CELG's Top Competitors

CELG $119.16 (-1.41%)
Current stock: CELG
AMGN $152.26 (-2.63%)
Current stock: AMGN
BIIB $389.16 (10.17%)
Current stock: BIIB
$0.00 (0.00%)
Current stock: